Detalles de la búsqueda
1.
Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
Cardiovasc Diabetol
; 20(1): 96, 2021 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33947390
2.
Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
Int J Mol Sci
; 20(22)2019 Nov 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31698825
3.
Ripasudil-Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials.
Am J Ophthalmol
; 248: 35-44, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36410471
4.
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
Aliment Pharmacol Ther
; 54(10): 1263-1277, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34528723
5.
Evaluation of Data Errors and Monitoring Activities in a Trial in Japan Using a Risk-Based Approach Including Central Monitoring and Site Risk Assessment.
Ther Innov Regul Sci
; 55(4): 841-849, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33876398
6.
Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin.
J Clin Endocrinol Metab
; 104(9): 3647-3660, 2019 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30811541
Resultados
1 -
6
de 6
1
Próxima >
>>